RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response. | LitMetric

RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response.

Maria Kallieri , Eleftherios Zervas , Evangelia Fouka , Konstantinos Porpodis , Marija Hadji Mitrova , Eleni Tzortzaki , Michael Makris , Maria Ntakoula , Andriana I Papaioannou , Panagiotis Lyberopoulos , Katerina Dimakou , Sofia Koukidou , Sevasti Ampelioti , Anastasia Papaporfyriou , Konstantinos Katsoulis , Maria Kipourou , Nikoletta Rovina , Katerina Antoniou , Stylianos Vittorakis , Petros Bakakos

Allergy

2nd Respiratory Department, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.

Published: September 2022

Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Download full-text PDF	Source
http://dx.doi.org/10.1111/all.15382	DOI Listing

Publication Analysis

Top Keywords

relight two-year

4

two-year real-life

4

real-life study

4

study mepolizumab

4

mepolizumab patients

4

patients severe

4

severe eosinophilic

4

eosinophilic asthma

4

asthma greece

4

greece evaluating

4

Similar Publications

RELIght: A two-year REal-LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response.

Allergy

September 2022

2nd Respiratory Department, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.

Maria Kallieri , Eleftherios Zervas , Evangelia Fouka , Konstantinos Porpodis , Marija Hadji Mitrova

View Article and Find Full Text PDF

Similar Publications